Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease — Stella

Home/Autoimmune Diseases/

View on ClinicalTrials.gov

Recruiting

Back to Autoimmune Diseases trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Key details

Phase

Very early testing

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Enrollment target

~15 participants

Started

April 2026

Primary completion

December 2028

Age range

3 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.